Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology for psychedelic therapy, has announced a follow-up strategic equity investment in ATMC Journey Centers Inc. (“ATMA”), the first government-approved psychedelic journey center in Canada. Earlier this year, MCUR had signed a letter of intent, securing 13% ownership in ATMA; this additional investment retains that ownership. In addition, the company named Mind Cure Health president and CEO Kelsey Ramsden to the ATMA board of directors. MINDCURE’s investment into the pioneering psychedelic journey center is meant to facilitate the use of iSTRYM (“iSTRYM”), which is MCUR’s proprietary AI-driven platform focused on patient feedback and data-driven insights into the efficacy of psychedelic treatments. The purpose of the technology is to assist in the application of more effective and more efficient diagnosis techniques and treatments. “We are extremely excited to strengthen our partnership with the team at ATMA through this investment,” said Mind Cure Health president and CEO Kelsey Ramsden in the press release. “This further solidifies the company’s strategic position in clinics and partnerships for the deployment of digital therapeutics to drive near-term revenues. ATMA’s team is a true pioneer in the psychedelic therapy industry by growing a global network of group and retreat psychedelic therapy clinics. ATMA’s established clinical footprint gives us the opportunity to deploy our iSTRYM technology, with the intended goal to optimize treatment for ATMA’s patients and obtain the data we need to build iSTRYM into the platform trusted by therapists and patients around the world.”
To view the full press release, visit https://ibn.fm/kSkLq
About Mind Cure Health Inc.
MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. The company believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care. MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity and enhance mental health. The company is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports and psychedelics, all to improve mental health. For more information about the company, please visit www.MindCure.com
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.